Cargando…

High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy

BACKGROUND: Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies have reported that increased CXCR4 expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shim, Bobae, Jin, Min-Sun, Moon, Ji Hye, Park, In Ae, Ryu, Han Suk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pathologists and the Korean Society for Cytopathology 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250928/ https://www.ncbi.nlm.nih.gov/pubmed/30269472 http://dx.doi.org/10.4132/jptm.2018.09.19

Ejemplares similares

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer
por: Lim, Seung Taek, et al.
Publicado: (2018)

Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients
por: Cai, Lifen, et al.
Publicado: (2020)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer
por: Prat, A, et al.
Publicado: (2014)

Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer
por: Oladeru, Oluwadamilola T., et al.
Publicado: (2020)

EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas
por: Li, Rong-Hui, et al.
Publicado: (2017)

Cytologic Diagnosis of Metastatic Alveolar Rhabdomyosarcoma in Cerebrospinal Fluid: A Case Report
por: Shim, Bobae, et al.
Publicado: (2018)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
por: Fu, Wen-Fen, et al.
Publicado: (2020)

Adjuvant chemotherapy, not radiotherapy, prolongs survival for node-negative non–small cell lung cancer with positive surgical margins
por: Ashrafi, Arman, et al.
Publicado: (2023)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
por: Bhattacharyya, G. S., et al.
Publicado: (2018)

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
por: Mori, Miki, et al.
Publicado: (2019)

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer
por: Bansal, GJ, et al.
Publicado: (2015)

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics
por: Gámez-Pozo, Angelo, et al.
Publicado: (2017)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
por: Xia, Lin-Yu, et al.
Publicado: (2020)

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
por: Si, Yingnan, et al.
Publicado: (2021)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer
por: Dabbagh, Najmeh, et al.
Publicado: (2022)

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2022)

A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism
por: Wang, Lu, et al.
Publicado: (2017)

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2022)

Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple‐negative breast cancer
por: Heeg, Erik, et al.
Publicado: (2019)

Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database
por: Zhang, Yuyuan, et al.
Publicado: (2023)

Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells
por: Yang, Meng, et al.
Publicado: (2019)

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
por: Vetter, Marcus, et al.
Publicado: (2017)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients
por: Jeong, Hae Min, et al.
Publicado: (2017)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
por: Bianco, Nadia, et al.
Publicado: (2021)

High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
por: Jääskeläinen, Anniina, et al.
Publicado: (2018)

PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease
por: Assaker, Gloria, et al.
Publicado: (2019)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

The advance of adjuvant treatment for triple-negative breast cancer
por: Ge, Jingyu, et al.
Publicado: (2022)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a1r3oab3fan473lm74i6mvrddv